Galmed Pharmaceuticals Ltd.

NasdaqCM:GLMD Stock Report

Market Cap: US$1.2m

Galmed Pharmaceuticals Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Allen Baharaff

Chief executive officer

US$1.4m

Total compensation

CEO salary percentage44.5%
CEO tenure24.2yrs
CEO ownershipn/a
Management average tenure7yrs
Board average tenure6.8yrs

Recent management updates

Recent updates

Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?

May 16
Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?

Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?

Jan 06
Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?

Galmed GAAP EPS of -$0.15 beats by $0.09

Aug 04

Companies Like Galmed Pharmaceuticals (NASDAQ:GLMD) Could Be Quite Risky

May 03
Companies Like Galmed Pharmaceuticals (NASDAQ:GLMD) Could Be Quite Risky

Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?

Jan 15
Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?

Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?

Oct 02
Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?

Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Invest In Growth?

May 20
Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Invest In Growth?

Galmed gets greenlight for late-stage Aramchol NASH trial in China

May 03

What Type Of Shareholders Own The Most Number of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Shares?

Feb 04
What Type Of Shareholders Own The Most Number of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Shares?

We Think Galmed Pharmaceuticals (NASDAQ:GLMD) Can Afford To Drive Business Growth

Dec 06
We Think Galmed Pharmaceuticals (NASDAQ:GLMD) Can Afford To Drive Business Growth

Galmed EPS misses by $0.02

Nov 12

CEO Compensation Analysis

How has Allen Baharaff's remuneration changed compared to Galmed Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2023n/an/a

-US$8m

Jun 30 2023n/an/a

-US$11m

Mar 31 2023n/an/a

-US$14m

Dec 31 2022US$1mUS$605k

-US$18m

Sep 30 2022n/an/a

-US$23m

Jun 30 2022n/an/a

-US$25m

Mar 31 2022n/an/a

-US$30m

Dec 31 2021US$3mUS$632k

-US$32m

Sep 30 2021n/an/a

-US$35m

Jun 30 2021n/an/a

-US$34m

Mar 31 2021n/an/a

-US$32m

Dec 31 2020US$1mUS$503k

-US$29m

Sep 30 2020n/an/a

-US$27m

Jun 30 2020n/an/a

-US$24m

Mar 31 2020n/an/a

-US$23m

Dec 31 2019US$1mUS$486k

-US$20m

Sep 30 2019n/an/a

-US$16m

Jun 30 2019n/an/a

-US$12m

Mar 31 2019n/an/a

-US$11m

Dec 31 2018US$2mUS$384k

-US$10m

Sep 30 2018n/an/a

-US$10m

Jun 30 2018n/an/a

-US$12m

Mar 31 2018n/an/a

-US$12m

Dec 31 2017US$1mUS$384k

-US$12m

Compensation vs Market: Allen's total compensation ($USD1.36M) is above average for companies of similar size in the US market ($USD661.47K).

Compensation vs Earnings: Allen's compensation has been consistent with company performance over the past year.


CEO

Allen Baharaff (58 yo)

24.2yrs

Tenure

US$1,358,503

Compensation

Mr. Allen Baharaff has been the Chief Executive Officer of Galmed Pharmaceuticals Ltd. since January 2012 and has been its President since March 2015. Mr. Baharaff co-founded the Galmed Pharmaceuticals Ltd...


Leadership Team

NamePositionTenureCompensationOwnership
Allen Baharaff
Co-Founder24.2yrsUS$1.36mno data
Doron Cohen
Chief Financial Officer2.1yrsUS$181.17k0%
$ 0
Guy Nehemya
COO & Data Protection Officer7yrsUS$350.21k0.0094%
$ 116.6
Yohai Stenzler
Chief Accounting Officer2.1yrsUS$354.14k0.0094%
$ 116.6
Liat Hayardeny
Chief Scientific Officer7.5yrsUS$239.89k0%
$ 0
Yael Hollander
Vice President of Legal Affairs & Strategy7yrsUS$215.79kno data
Shani Ganon
Human Resources Managerno datano datano data
Tali Gorfine
Medical Consultant7yrsUS$382.51kno data

7.0yrs

Average Tenure

53yo

Average Age

Experienced Management: GLMD's management team is seasoned and experienced (7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Allen Baharaff
Co-Founderno dataUS$1.36mno data
David Sidransky
Lead Independent Director9.8yrsno data0.012%
$ 155.5
Carol Brosgart
Independent Director6.8yrsno data0%
$ 0
José Mato de la Paz
Member of Scientific Advisory Boardno datano datano data
Scott L. Friedman
Member of Scientific Advisory Boardno datano datano data
Arun Sanyal
Member of Scientific Advisory Boardno datano datano data
Vlad Raziu
Member of Scientific Advisory Boardno datano datano data
Shmuel Nir
Independent Director17.2yrsno data0.012%
$ 155.5
Rohit Loomba
Member of Scientific Advisory Boardno datano datano data
Ran Oren
Member of Scientific Advisory Board3yrsno datano data
Amir Poshinski
Independent Director3.8yrsno data0.0042%
$ 52.0
Shomron Ben-Horin
Member of Scientific Advisory Boardno datano datano data

6.8yrs

Average Tenure

62yo

Average Age

Experienced Board: GLMD's board of directors are considered experienced (6.8 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.